ArticleInflammopharmacology2026
Combatting psoriasis with nanomedicine: gamma-amino butyric acid-chitosan nanoparticles as a targeted anti-psoriatic therapy.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chronic inflammation and oxidative stress are the most deleterious pathogenic factors of psoriasis (PS). While gamma-aminobutyric acid (GABA) possesses well-documented immunomodulatory and antioxidant properties, its therapeutic potential is limited by bioavailability and targeting. Chitosan nanoparticles (CSNP) offer a promising drug delivery platform to overcome GABA limitations. This study aimed to augment the dermatological efficacy of GABA by encapsulation within CSNPs to overcome its skin penetration limitations, thereby creating an advanced transdermal delivery system for sustained anti-psoriatic local action. TEM revealed spherical, monodisperse GABA-CSNPs. Dynamic light scattering (DLS) confirmed a nanoscale size (57.63 nm), highly positive surface charge (+ 35.93 mV) and excellent colloidal stability. In vitro, GABA-CSNPs demonstrated superior antioxidant (using 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay) and anti-inflammatory (membrane stabilization) activities compared to free GABA or blank CSNPs, beside enhanced biocompatibility (using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay). A PS-like model was induced in rats using 5% imiquimod (IMQ). Animals were divided into five groups: negative control, psoriatic control (PC) (62.5 mg of Aldara® cream) and IMQ groups treated with free GABA ( 200 mg/kg), unloaded CSNPs (100 mg/kg), or GABA-CSNPs (100 mg/kg). The GABA-CSNPs treatment group showed the most significant clinical improvement, reducing scaling and erythema. Mechanistically, therapy restored epidermal architecture, ameliorated oxidative stress by lowering malondialdehyde (MDA) and elevating superoxide dismutase (SOD) and catalase (CAT) levels, and potently suppressed key pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) in skin tissue. In conclusion, GABA-CSNPs constitute a novel and highly effective antipsoriatic nanotherapeutic platform. The formulation synergizes the inherent bioactivity of GABA with the enhanced delivery and targeting capabilities of CSNPs, resulting in a potent dual-action therapy that alleviates oxidative damage and modulates the dysregulated immune response central to psoriatic pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.